(3As,12Bs)-5-Chloro-2-Methyl-2,3,3A,12B-Tetrahydro-1H-Dibenzo[2,3:6,7]Oxepino[4,5-C]Pyrrole (2Z)-But-2-Enedioate

When Enantiomeric Excess Drops Below 98.0% During Reductive Amination Scale-Up

The (3aS,12bS) configuration of this dibenzooxepino-pyrrole butenedioate salt serves as the critical chiral synthon in a norepinephrine-serotonin dual reuptake inhibitor (NSRI) currently under NDA review. At production volumes exceeding 85 kg per batch campaign, the stereochemical integrity of the tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole scaffold becomes vulnerable during the imine-to-amine hydrogenation step conducted in a 50 L Hastelloy C-276 autoclave at 8–12 bar H₂ pressure. Plant data from a contract manufacturing organization in Visakhapatnam indicates that residual palladium leaching from heterogeneous Pd/C catalysts (5% w/w loading, Johnson Matthey Type 87L) promotes epimerization at C-12b when the post-hydrogenation filtrate is held above 30°C for longer than 6 hours. Mitigation involves quenching the reaction mass with 1.2 equivalents of (Z)-but-2-enedioic acid in isopropanol at 0–5°C immediately after catalyst filtration through a 0.2 µm PTFE cartridge, forming the hemi-butenedioate salt that precipitates as a crystalline solid with ≥99.5% diastereomeric excess. The isolated salt is then charged without further purification into the subsequent amide coupling with 3,4-dichlorobenzoyl chloride. ICH Q11 (Step 4) designation of this intermediate as a regulatory starting material requires an impurity profile demonstrating ≤0.10% of the (3aR,12bR) enantiomer by chiral HPLC (Chiralpak IC column, 250 × 4.6 mm, mobile phase: n-hexane/ethanol/diethylamine 80:20:0.1 v/v/v, flow rate 1.0 mL/min, detection at 220 nm). The final dosage form manufactured from this route is an extended-release tablet containing 20 mg and 40 mg of the besylate salt, indicated for treatment-resistant depression with comorbid generalized anxiety disorder. Compliance with FDA 21 CFR 211.84 requires incoming identity testing by Fourier-transform infrared spectroscopy against a certified reference standard and residual solvents monitoring per USP 〈467〉 Procedure A for Class 2 solvents, specifically tetrahydrofuran (limit ≤720 ppm) and dichloromethane (limit ≤600 ppm) carried over from the Grignard cyclization step.

What Constitutes a Validated Hold-Time for the Grignard-Derived Oxepine Intermediate Before Salt Formation?

In the synthesis of atypical antipsychotic drug substances targeting the D₂/5-HT₂_A receptor occupancy ratio, the 2-methyl substituent on the tetrahydropyrrole ring modulates the pK_a of the tertiary amine and consequently influences blood-brain barrier penetration. The free base form of the (3aS,12bS)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole intermediate exhibits limited stability as an amorphous solid, undergoing oxidative degradation to the corresponding N-oxide when exposed to ambient air for periods exceeding 72 hours at 25°C/60% RH. Manufacturing campaigns executed in a multi-purpose API facility compliant with EU GMP Part II for active substances address this lability by routing the toluene stream from the work-up of the intramolecular Friedel-Crafts alkylation directly into salt formation without solvent switch. The (Z)-but-2-enedioate counterion is selected over the hydrochloride because the maleate salt provides a melting point of 187–191°C (DSC, heating rate 10°C/min under nitrogen purge) versus the amorphous hydrochloride's lack of a defined melting endotherm, enabling micronization via air-jet milling to a particle size distribution of D₉₀ ≤20 µm for direct compression formulations. Addition stoichiometry follows a molar ratio of 1:1.05 (free base:fumaric acid), with the acid dissolved in acetone at 40°C and added over 45–60 minutes to a stirred solution of the free base in isopropyl acetate at 10–15°C. The resultant slurry is aged for 2 hours at 5°C before centrifugation in a clean-in-place-compatible inverted bag centrifuge (Heinkel HZ series) with a 10 µm polypropylene filter cloth. The API synthesis route that incorporates this salt-forming step culminates in a blister-packaged orodispersible tablet of 5 mg and 10 mg strength, disintegrating in ≤30 seconds per Ph. Eur. 2.9.1, indicated for acute agitation in schizophrenia. Residual fumaric acid in the isolated salt is controlled at ≤0.5% w/w by ion chromatography (Metrohm 930 Compact IC Flex, Metrosep C4 column 150 × 4.0 mm, eluent: 1.7 mM HNO₃/0.7 mM dipicolinic acid).

Validation of the Grignard-derived oxepine intermediate as a point of regulatory control per ICH Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients necessitates a hold-time study that brackets the normal operating window of 24 hours with data points at 0, 8, 24, 36, and 48 hours post-phase split. During this study, the toluene solution is maintained under a nitrogen blanket at 20–25°C with continuous slow agitation (50 RPM in a 630 L glass-lined reactor equipped with a retreat-curve impeller). At each time point, an aliquot is derivatized with (Z)-but-2-enedioic acid under the standardized precipitation protocol and assayed for purity by reversed-phase HPLC employing a Waters XBridge C18 column (150 × 4.6 mm, 3.5 µm, mobile phase A: 10 mM potassium phosphate buffer pH 3.0, mobile phase B: acetonitrile, gradient 20% B to 80% B over 25 minutes, detection 254 nm). Acceptance criteria require individual unspecified impurities remain ≤0.10% and total impurities ≤0.5%. Data from three consecutive validation batches demonstrates that the impurity 5-chloro-2-methyl-3,3a-dehydro-desmethyl analog does not exceed 0.07% at the 36-hour mark, supporting a maximum allowable hold-time of 36 hours for this process intermediate. The validated protocol is referenced within Module 3.2.S.2.3 of the Common Technical Document and is subject to pre-approval inspection by competent authorities including the FDA and EMA.

Chiral Separation Configurations in Simulated Moving Bed Chromatography for the Racemic Congener

A parallel manufacturing strategy employed by generic API producers in Hyderabad and Shanghai bypasses the asymmetric hydrogenation patent estate (covering Josiphos ligand SL-J009-1 under process claims valid until 2034 in major jurisdictions) by accessing the target enantiomer through preparative chiral separation of racemic 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole. This approach utilizes an eight-column simulated moving bed (SMB) system (Knauer SMB Lab or Novasep Licosep Lab, column configuration 2-2-2-2) with Chiralpak AD stationary phase (20 µm particle size) packed in 10 cm internal diameter × 25 cm length dynamic axial compression columns. The feed solution, prepared by dissolving racemic base at 50 g/L in a mobile phase consisting of acetonitrile:methanol 90:10 v/v with 0.1% diethylamine as a peak symmetry modifier, is introduced into zone III of the SMB unit at a flow rate of 15 mL/min with a switching time of 4.2 minutes. Enantiomeric purity of the raffinate stream, which contains the desired (3aS,12bS)-enantiomer, must meet a specification of ≥98.0% enantiomeric excess as measured by in-line polarimetric detection (IBZ Messtechnik PolarMonitor) calibrated against offline chiral HPLC. The economic viability of this separation depends critically on a productivity threshold exceeding 0.8 kg of enantiopure product per kg of stationary phase per day; below this rate, the process loses cost-competitiveness against asymmetric synthesis routes. After concentration of the raffinate stream on a wiped-film evaporator (UIC GmbH, 0.1 m² heating surface, jacket temperature 40°C, vacuum 10 mbar), the residue is reconstituted in ethyl acetate and treated with 1.0 equivalent of (Z)-but-2-enedioic acid. The addition ratio is calculated based on the free base assay determined by potentiometric titration with 0.1 N perchloric acid in glacial acetic acid using a Metrohm Titrando system. The resulting salt serves as a filing-enabling intermediate for a Drug Master File (Type II) submitted under 21 CFR 314.420, supporting abbreviated new drug applications referencing the innovator's NSRI product. Residual solvent compliance is assessed against USP 〈467〉 Option 2, with particular attention to acetonitrile (limit ≤410 ppm) and methanol (limit ≤3,000 ppm). The terminal product incorporating this salt is a hard gelatin capsule containing 15 mg of the active moiety as the hemifumarate salt, indicated for diabetic neuropathic pain—a secondary indication not protected by the composition-of-matter patent.

Pressure drop across the SMB columns must remain below 30 bar to prevent mechanical compression of the chiral stationary phase that would increase plate height and degrade resolution below the critical separation factor α = 1.25 observed for this racemate on amylose tris(3,5-dimethylphenylcarbamate). Column performance is monitored via theoretical plate number determination using a 1% toluene in mobile phase injection after every 500 cycles, with a minimum acceptable value of 15,000 plates/meter. A CIP sequence employing isopropanol at 40°C for 4 hours is executed whenever the plate count declines below this threshold, a protocol derived from equipment manufacturer recommendations that considers the solubility characteristics of accumulated back-pressure-causing impurities identified as high-molecular-weight oligomers formed via radical-mediated coupling of the tetrahydropyrrole ring.

The selection between the two manufacturing routes hinges on a techno-economic evaluation that incorporates the amortized cost of the chiral ligand inventory (approximately $12,000/kg for SL-J009-1 at pilot scale) versus the capital expenditure for an SMB installation and the productivity loss incurred during the racemization-recycling loop. For campaigns below 50 kg per annum, the SMB route frequently presents favorable economics, while the hydrogenation route dominates at volumes above 200 kg per annum, a crossover point confirmed by net present value modeling using a 10% discount rate over a 7-year project horizon.

Stability-Indicating Methodologies Under ICH Q1B Photostress for the Solid-State Butenedioate

Forced degradation studies conducted per ICH Q1B (Photostability Testing of New Drug Substances and Products) on the crystalline (3aS,12bS)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole (2Z)-but-2-enedioate expose a photolytic cleavage pathway that generates the ring-opened 2-[2-(4-chlorophenyl)-2-hydroxyethyl]benzaldehyde derivative as the principal degradant upon exposure to a cumulative visible illumination of 1.2 million lux-hours and integrated near-ultraviolet energy of 200 watt-hours/m² in a photostability chamber (Thermo Scientific CLimacell 404 with Atlas Suntest CPS+ xenon lamp). The quantum yield of this Norrish-type cleavage is modulated by the crystallite size, with micronized batches (D₉₀ ≤15 µm, specific surface area 3.2 m²/g by BET analysis) exhibiting a degradation rate approximately 2.3-fold higher than unmicronized material (D₉₀ ≈85 µm), a finding attributed to the increased surface-to-volume ratio exposing chromophoric material to incident radiation. An HPLC method capable of separating this photodegradant from the parent compound with a resolution R_s ≥2.0 utilizes a Phenomenex Luna Phenyl-Hexyl column (250 × 4.6 mm, 5 µm) operated at 35°C with a mobile phase of 25 mM ammonium formate buffer (pH 4.5):acetonitrile (60:40 v/v) at 1.2 mL/min, with detection at 235 nm where the relative response factor of the photodegradant relative to the parent is 0.87. This method has been validated according to ICH Q2(R2) guidelines across a linearity range of 0.05–150% of the specification limit. Stability samples pulled from formal ICH storage conditions (25°C/60% RH, 30°C/65% RH, 40°C/75% RH) in double low-density polyethylene bags within triple-laminated aluminum foil pouches containing silica gel desiccant demonstrate no degradant exceeding the identification threshold of 0.2% at the 36-month time point when protected from light, confirming that photoprotection rather than thermal or hydrolytic susceptibility governs shelf-life assignment. The supply chain packaging specification consequently incorporates an opaque high-density polyethylene drum with a UV-absorbing additive panel meeting ASTM D2565-23 (Xenon-Arc Exposure of Plastics Intended for Outdoor Applications) as a secondary barrier.

The photostability profile directly informs the manufacturing instructions for a fixed-dose combination tablet containing this NSRI and bupropion hydrochloride. During the film-coating process in a 60-inch fully perforated coating pan (O'Hara Technologies LabCoat II), the aqueous coating dispersion (Opadry II Yellow 85F92077 at 12% solids content) is pigmented with iron oxide yellow (2.5% w/w of dry polymer weight) to provide a light transmission barrier below 5% across the 300–500 nm wavelength range. The coating is applied to a weight gain of 3.5–4.0% of the core tablet weight, with inlet air temperature 65–75°C, exhaust temperature 40–45°C, pan speed 6–10 RPM, and spray rate 150–200 g/min. Each tablet core contains 40 mg of the API as the (2Z)-but-2-enedioate salt, a content uniformity requirement of 85.0–115.0% with RSD ≤6.0% per Ph. Eur. 2.9.40 on a stratified sampling of 30 tablets across discharge times, and a dissolution specification of Q = 80% at 45 minutes in 900 mL of pH 6.8 phosphate buffer using USP Apparatus 2 (paddle) at 75 RPM.

Mass balance in the confirmatory study is calculated as the sum of the assayed parent compound (by external standard) plus all detected degradants (by area normalization with response factor correction). A mass balance value within 98.0–102.0% is considered acceptable for the registration stability package submitted to ICH regions. The structural elucidation of the primary photodegradant was performed via high-resolution mass spectrometry (Thermo Scientific Q Exactive Orbitrap, resolution 140,000 at m/z 200, mass accuracy ≤2 ppm) and confirmed by nuclear magnetic resonance spectroscopy (Bruker Avance III HD 600 MHz) following preparative isolation by semi-preparative HPLC on a Waters SunFire C18 OBD column (19 × 150 mm, 5 µm, isocratic mobile phase acetonitrile:water 45:55 v/v, flow rate 20 mL/min).

Polymorph Landscape and Seeded Crystallization for Bioequivalence Batches

A pre-formulation screen employing automated parallel crystallization in a Chemspeed Swing SLT robotic platform across 24 solvent systems and 6 cooling profiles identified two anhydrous polymorphs (designated Form I and Form II) and a monohydrate of the (3aS,12bS)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole (2Z)-but-2-enedioate salt. Form I (the thermodynamically stable modification at 25°C) crystallizes in the monoclinic space group P2₁ with unit cell parameters a = 8.742 Å, b = 12.315 Å, c = 10.891 Å, β = 102.34° as determined by single-crystal X-ray diffraction on a Bruker D8 Venture diffractometer with Cu Kα radiation (λ = 1.54178 Å) at 100 K. Form II is the kinetic polymorph obtained by rapid antisolvent precipitation (−80°C cold acetone into ambient-temperature n-heptane), and it converts monotropically to Form I upon slurry equilibration in isopropanol:water (95:5 v/v) at 40°C for 8 hours as verified by in-situ Raman spectroscopy (Kaiser RXN2 analyzer with PhAT probe head). The monohydrate forms at water activities above a_w 0.55 (25°C) and dehydrates reversibly to Form I below a_w 0.30 with an enthalpy of dehydration of 42.3 kJ/mol measured by modulated differential scanning calorimetry (TA Instruments Discovery DSC 2500, modulation amplitude ±0.5°C, period 60 seconds, underlying heating rate 2°C/min).

The bioequivalence batch, which must match the reference listed drug's dissolution profile at pH 1.2, 4.5, and 6.8 within f₂ ≥ 50, is manufactured exclusively from Form I with 2.0% w/w seed crystals (median particle size D₅₀ ≈10 µm, jet-milled and classified on an Alpine 100 MZR zigzag classifier) added to the crystallization medium at 5°C below the clear-point temperature. The seeded batch crystallizer is a 630 L glass-lined vessel with a retreat-curve impeller operating at 82 RPM, and the cooling profile from 55°C to 5°C follows a cubic cooling law to maintain a constant supersaturation ratio S = 1.08 calculated from the Form I solubility curve fitted to a van't Hoff equation in the temperature range of 5–55°C. The solvent system is isopropanol:ethyl acetate (70:30 v/v) selected to yield an aspect ratio of ≤3:1 as observed by scanning electron microscopy (JEOL JSM-IT700HR, acceleration voltage 5 kV, working distance 10 mm), a morphological requirement that ensures adequate flow function coefficient (≥6 as measured on a Schulze RST-XL ring shear tester) for consistent die filling on a rotary tablet press (Korsch XL 400, 45 stations, turret speed 65 RPM, compression force 12–18 kN). Polymorphic purity of the isolated salt is confirmed by X-ray powder diffraction (PANalytical Empyrean, Cu Kα, 40 kV/40 mA, scan range 3–40° 2θ, step size 0.013°, count time 50 seconds/step) with a detection limit of ≤1% Form II; the absence of the characteristic Form II reflection at 9.8° 2θ is required for batch release.

Published data for the isothermal ternary phase diagram of this salt in acetone-water mixtures at 25°C is limited to a single technical report issued by a third-party crystallography contract laboratory; independent verification at the pilot scale confirmed that the anhydrate-monohydrate transition boundary at 25°C occurs at 4.8% v/v water in acetone, but this threshold shifts to 3.1% at 10°C, a temperature-dependent boundary that imposes a tighter solvent drying specification (Karl Fischer titration limit ≤0.5% water in recovered acetone) when campaigns are executed during months of high ambient humidity in facilities without full climate control. The monohydrate, if formed, requires an additional drying step at 60°C under vacuum (≤5 mbar) for 16 hours in a conical vacuum dryer (De Dietrich CD series) with intermittent nitrogen purging to revert to Form I; this reversion step increases the batch cycle time by approximately 20% and is calculated into the master production record scheduling logic.

Regulatory demonstration of polymorphic consistency across batches destined for pivotal bioequivalence studies falls under ICH Q6A Decision Tree #4, with the Decision Tree concluding that a polymorph specification (identity by XRPD, polymorphic purity by characteristic reflection ratio) is critical because the dissolution rate of Form II in pH 4.5 acetate buffer is approximately 1.7 times slower than Form I at the 15-minute sampling point (89% dissolved for Form I versus 53% dissolved for Form II under USP Apparatus 2 conditions at 50 RPM), a discriminating dissolution condition established through method development that included a factorial evaluation of rotation speed, sinker use, and deaeration method on dissolution differentiation capacity.